Core Viewpoint - Hims & Hers has acquired a pharmacy to expand its product line and reduce costs, marking the company's second major vertical integration, which is expected to drive growth [1] Group 1 - The acquisition allows Hims & Hers to enter new markets [1] - The move is anticipated to lower costs for the company [1] - This is the second significant step in vertical integration for Hims & Hers [1]

Group 1 - The stock of Hims & Hers Health, Inc. (HIMS) closed at $16.28, reflecting a decrease of -1.75% from the previous day's closing price, underperforming the S&P 500 which gained 0.13% [1] - Over the past month, HIMS stock has increased by 6.35%, outperforming the Medical sector's gain of 3.34% and the S&P 500's gain of 3.67% [1] Group 2 - Hims & Hers Health, Inc. is expected to report an EPS of $0.06, representing a 250% increase from the same quarter last year, with revenue forecasted at $378.82 million, indicating a 67.1% year-over-year increase [2] - For the full year, analysts project earnings of $0.22 per share and revenue of $1.39 billion, reflecting changes of +300% and +59.79% respectively from the previous year [3] Group 3 - Recent changes to analyst estimates for Hims & Hers Health, Inc. suggest a positive outlook for the company's business trends, with upward revisions indicating optimism [4] - The Zacks Rank system, which incorporates estimate changes, currently assigns Hims & Hers Health, Inc. a rank of 3 (Hold) [6] Group 4 - Hims & Hers Health, Inc. has a Forward P/E ratio of 77.01, which is a premium compared to the industry's average Forward P/E of 26.93 [7] - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [7]

The healthcare company will be making more of the product it sells. Shares of healthcare company Hims & Hers Health (HIMS 2.85%) jumped as much as 23.9% this week after news of closing a large acquisition. According to data provided by S&P Global Market Intelligence, shares are up 18.3% for the week as of 2:30 p.m. ET. Hims & Hers gets deeper into compounding The biggest news was Hims & Hers issuing 976,341 shares of common stock to acquire Nivagen Pharmaceuticals, which does business as MedisourceRX. The c ...

Core Viewpoint - Hims & Hers Health is experiencing a decline in stock price despite solid growth results, raising questions about its future potential and valuation [1][2]. Company Performance - Hims & Hers has significantly grown its subscriber base to approximately 1.9 million, contributing to a revenue increase of 52% year-over-year, reaching $315.6 million for the quarter ending June 30 [2][3]. - The company is exploring additional markets such as diabetes, fertility, and pain management, which could further enhance its growth trajectory [4]. Market Opportunities - The company is targeting the weight loss market by providing access to GLP-1 treatments, which may boost short-term sales despite potential legal risks [4]. - Analysts project a potential upside of over 45% for Hims & Hers stock based on a consensus price target exceeding $20, indicating room for growth in the next 12 months [5]. Valuation Considerations - Hims & Hers is trading at a forward price-to-earnings ratio of 32, higher than the average healthcare stock at 22, suggesting a premium valuation that may be justified by its growth prospects [6]. - Sustaining a growth rate of over 20% in the long term could maintain investor interest despite current valuation concerns [6]. Long-term Outlook - The company is positioned for long-term growth by addressing sensitive healthcare issues and building customer trust, which may lead to increased upselling opportunities [7]. - Despite short-term challenges and high valuation, Hims & Hers could be a compelling investment if it continues to demonstrate strong growth [9].

Core Insights - The COVID-19 pandemic significantly increased the demand for telemedicine services, benefiting companies like Teladoc Health [3][4] - Hims & Hers Health has emerged as a new player in the telemedicine space, focusing on areas like mental health and weight loss [5][8] - The company's stock has seen volatility, with a 63% gain in early 2024 followed by a 40% decline since mid-June [9] Company Overview - Hims & Hers Health was founded in 2017 and initially focused on over-the-counter medications and personal care products [5] - The company went public in 2021 through a reverse merger with a SPAC [5] - Hims & Hers aims to differentiate itself by addressing gaps in mental health services and prescription weight loss medications [6][7] Market Dynamics - The healthcare market is highly competitive, with significant opportunities in mental health and weight loss services [6][7] - Hims & Hers has ventured into behavioral health and weight loss, potentially positioning itself to disrupt traditional healthcare models [8] - The company's recent focus on weight loss alternatives may impact its stock performance and market perception [10][12] Financial Performance - Hims & Hers management has increased its 2024 revenue and adjusted EBITDA projections, indicating strong demand for its services [11] - Despite recent growth, there are concerns about the sustainability of this momentum in the face of competition from big pharmaceutical companies [12][13] - The company's strategy of offering lower-cost solutions in emerging healthcare areas is viewed as ambitious but uncertain [13]

Group 1: Market Conditions and Investment Opportunities - Volatility is crucial for both traders and long-term value investors, as it often leads to lower stock prices, creating potential buying opportunities [1] - Retail investors can capitalize on discounted stocks during high volatility, with NexGen Energy, Wayfair, and Hims & Hers identified as potential buys [2] - The U.S. economy is cooling, with unemployment at 4.3% and inflation at 2%, leading to expectations of interest rate cuts by September 2024, which may trigger a new bull market in oil [3] Group 2: Company-Specific Insights - NexGen Energy is currently priced at $5.32, with a 12-month price target of $11.00, indicating a potential upside of 106.77% [4][5] - Wayfair's stock is trading at $43.18, with a price target of $65.63, suggesting a 51.98% upside as interest rate cuts are expected to boost the real estate market [6][7] - Hims & Hers Health is priced at $13.96, with a price target of $20.29, representing a 45.31% upside, despite recent competition from Eli Lilly [8][9]

Hims & Hers Health, Inc.'s (HIMS) investors are encountering some short-term losses from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have plunged 32.1% in the past three months, underperforming the industry's 11.4% gain. In the same time frame, the stock underperformed the sector and S&P 500's 4.7% and 2.7% growth, respectively. Two major developments from HIMS in recent months include the announcement of its second-quarter 2024 results (in August) and the addition ...

Sales growth could accelerate now that it provides lower-cost, weight-management drugs. If you'd like to become a billionaire, paying attention to how other billionaires invest is a sensible way to get started. Everyday investors can easily keep tabs on billionaire stock purchases because the U.S. Securities and Exchange Commission (SEC) makes them disclose their trading activity every three months. In the latest round of disclosures, it's clear that a handful of funds run by billionaire investors bought sh ...

PM Images/DigitalVision via Getty Images Markets appear to have shaken off the fears stemming from U.S. recession talk and the unwinding of the Japan carry trade, but a number of stocks still remain well off their recent highs. Hims & Hers Health, Inc. (NYSE:HIMS), the maker and distributor of generic medicines, is one of the most notable names in this bucket. The stock has been rocked after reporting Q2 results, primarily on concerns that its revenue projections for its GLP-1 weight loss compounds are over ...

Wall Street is missing the forest for the trees, and the opportunity is enormous. The injectable weight loss drugs known as GLP-1 agonists have taken the world by storm. And the stocks of the companies making the drugs have crushed the market over the past couple of years. However, an industrywide shortage for the drugs opened the door for companies like Hims & Hers Health (HIMS -0.83%) to compete by offering lower-priced compounded versions mixed up by their teams. Hims & Hers stocks took flight once the c ...